Purple Biotech (PPBT) has released an update.
Purple Biotech Ltd. has announced encouraging interim results from their Phase 2 study on CM24, a novel anti-CEACAM1 antibody, showing significant improvements in overall survival and other efficacy endpoints for patients with metastatic pancreatic cancer. The combination therapy of CM24 with nivolumab and standard chemotherapy not only prolonged life but also reduced the risk of disease progression. These promising results suggest a potential new treatment avenue for pancreatic cancer patients, who currently have a very poor prognosis.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
